Sensors for Chemical and Biological Detection

 

化学的検出と生物学的検出のためのセンサー
あらゆる環境から高品質で複雑な情報を提供する

化学センサーや生物学的センサーは、生物兵器に対する防衛、ポイントオブケア診断、食品業界、環境監視など、精密で信頼性の高い分析が必要とされる各種の応用分野で重要な監視ツールとしての役割を担っています。このカンファレンスプログラムでは、リアルタイム検出機能を通じてセンサーの特異性と精度を維持しつつ、製造原価を引き下げるうえでの課題などが議論されます。

12月10日(火)

7:30 am Registration and Morning Coffee

全体セッション

8:20 Chairperson's Remarks

Christopher Hartshorn, PhD, Program Director, Cancer Treatment & Diagnosis, National Institutes of Health; National Cancer Institute

8:30 Wear, implant and analyze: sensors and the future of chronic care

Rafael Carbunaru, PhD, Vice President R&D, Boston Scientific

As rates of chronic disease climb, so do opportunities for wearable and implantable solutions to help manage them. Core technology and sensor improvements; integration into healthcare systems; robust security; and personalized experience could all speed adoption. This talk will address current market and opportunities, and include examples of using wearables, sensors and analytics in a proof-of-concept clinical study and life-saving AI for chronic disease applications.

9:00 Regulatory Considerations during Mobile Medical App Development for Commercial and Clinical Trial Use

Mike Benecky, Senior Director, Global Regulatory Affairs in Precision and Digital Medicine, GlaxoSmithKline

Mobile medical apps are defined as medical devices from their intended use. Mobile medical app regulation is health risk-based to balance patient safety and barriers to technological innovation. Medical device patient risk analysis is a critical prerequisite prior to sensor/app inclusion within a clinical trial. Key components of quality management systems for mobile medical apps include: software requirements/specifications, user acceptance testing, software postmarket surveillance, software version control, and medical device adverse event reporting.             

9:30 Nanotechnology, MEMS, Microfluidics for Health 4.0 Hypermobility

Anita Rogacs, PhD, Head of Life Sciences Strategy and R&D, HP Labs

New imperatives of healthcare are focusing on prevention, personalization of diagnostics and treatment, and democratization, including access to everyone, anywhere, anytime at a low cost. The technology convergence in medicine is enabled by the powerful combination of microelectronics, microfluidics, advanced (bio)-chemistry, distributed network, and data analytics.

10:00 Networking Coffee Break

10:30 Roundtable Discussions

Roundtable discussions are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Each topic is led by a moderator who ensures focused conversation around the key issues of that topic. Attendees choose to join a specific group.

TABLE 1: How Biosensors Can Address Global Health Challenges

Lisa Diamond, CEO, Pinpoint Science LLC

  • Where can access to biosensor solutions save lives in the developing world?
  • How can novel biosensor technologies contribute to fighting emerging pandemic threats?
  • What new tools can be offered to consumers to monitor and diagnose their own health status?
  • How do we best handle data collected from connected biosensors, protecting patient privacy while informing public health agencies?
  • What new applications for biosensors are needed in veterinary medicine, agriculture and food safety? 

Table 2: Power Solutions for Miniaturized Implants

Robert Rubino, Senior Director, Research and Development, Integer

  • How can we improve power technology to make powered implants smaller and more convenient?
  • What wireless power solutions are available?
  • What new battery and capacitor solutions are available that enable smaller devices?
  • What are the technical hurdles that these new technologies need to overcome and how do we get there?

Table 3: Mixed-Signal Application Specific Integrated Circuits (ASICs): Advantages, Challenges, Justification, and Strategies

Andrew Kelly, BSEE, Director of Applications Engineering, Semiconductor Division, Cirtec Medical

  • What advantages are offered by Application Specific Integrated Circuits (ASICs)?
  • What are the primary challenges associated with an ASIC-based design?
  • What are the most common applications that justify the challenges of an ASIC-based design?
  • How do you approach the system/circuit partition when developing an ASIC-based design?
  • What factors should be considered when deciding to either work with an ASIC supplier or develop an ASIC in-house?
  • What are the most important factors when selecting an ASIC supplier?

Table 4: Overcoming the Challenges to Bringing Medical Devices to The Market

David DiPaola, Managing Director, DiPaola Consulting

  • What were your biggest challenges bringing a medical device to market and what solutions did you implement?  
  • How were you able to expedite the FDA approval process and when in the development did you get the FDA involved?  
  • How do you recommend shorting the time to market for a medical device?  
  • What issues did you face in pilot production that were not identified in in the development stage and what steps did you take to address this?
  • How did you incorporate manufacturing, test and dimensional measurement requirements into your design up front?  What tools did you use?  

Table 5: Advanced Materials

Stacey Standridge, PhD, Deputy Director, National Nanotechnology Coordination Office

  • What advanced materials are you working with?
  • What specific performance, cost, or other benefits are you targeting with these materials?
  • What are the bottlenecks in deploying advanced materials in devices (e.g., technical performance, manufacturing scale, reproducibility, integration, standards, financial considerations)
  • What are potential mechanisms to address these bottlenecks?
  • What lessons can be learned from prior technologies in evolution of scale, reproducibility, and quality control? Are there any new challenges that are unique to your advanced material?

Table 6: Sensors for Collaborative or Autonomous Systems: Challenges and Considerations

Tom Calef, CTO, Activ Surgical

  • What industries are exploring such systems and what can be learned from them?
  • What sensor types and circuit architectures are well-suited for such systems?
  • What factors should be considered when deciding to either work with a sensor supplier or develop in-house?
  • What are current user-acceptance or regulatory/compliance challenges and successful case studies for overcoming them?
  • How is data being collected, stored, and used in today’s learning models?  What are the best practices for specific industries?
  • What is required for these systems to take the next “big leap” into Level 3 autonomous behavior or beyond?

革新的な生物学的検出技術と課題

11:25 Chairperson's Remarks

Phillip M. Mach, Analytical Chemist, US Army

11:30 Selective and Reversible Biodetection in Complex Matrices - Synergistic Roles of Biology and Electronics

Radislav Potyrailo, PhD, Principal Scientist, Chemical & Biological Sensing Lab, GE Global Research Center

We are developing aptamer-based biosensors to achieve new performance capabilities. Aptamers are single-stranded nucleic acids folded into their 3D conformations governed by their sequence and environmental conditions. Here, we will discuss our progress in three directions. First, we enhance biodetection selectivity in complex environments. Second, we introduce our innovative methodology for selection of aptamers.Third, we introduce the highly desired reversibility of biosensors.

12:00 pm eRAPID technology - a universal electrochemical sensor platform

Pawan Jolly, PhD, Senior Scientist, Wyss Institute, Harvard University

Affinity-based electrochemical sensors offer great potential for the development of multiplexed point-of-care (POC) diagnostics; however, their commercialization has been limited because these devices rapidly lose sensitivity due to biofouling in complex biological fluids.   Here we describe a simple drop-casting method that may be used to create sensor coatings that provide potent antifouling properties while retaining electrode conductivity in human blood and plasma.

12:30 Sponsored Presentation (Opportunity Available)

1:00 Enjoy Lunch on Your Own

革新的な生物学的検出技術と課題 (続き)

1:55 Chairperson's Remarks

Phillip M. Mach, Analytical Chemist, US Army

2:00 FEATURED PRESENTATION: Multifunctional Sensor Platform Enabled by Additive Manufacturing

Mahmooda Sultana, PhD, Associate Branch Head, Instrument Systems Engineering Branch, NASA Goddard Space Flight Center

In this talk, I will discuss our work on multifunctional sensor platform with a suite of environmental sensors fabricated with a variety of nanomaterials using additive manufacturing techniques. The platform is capable of sensing a variety of environmental parameters including pressure, temperature and target gases, and then transmitting the data via a wireless antenna. This technology has numerous space and terrestrial applications.

2:30 Nanotechnology Innovations Converging to Disrupt Multi-Gas Sensing

Sundip R. Doshi, Founder & CEO, AerNos, Inc.

Multiple industries have mission critical needs for affordable, effective multi-gas monitoring capabilities. Breakthroughs in nanotechnology using MEMS circuitry, hybrid nanostructures and signal processing deliver gas sensors that dramatically improve monitoring capabilities. This presentation will use AerNos AerN2S technology to illustrate and explore gas sensor application challenges, including low level detection, size, cross-contamination, calibration, real-time, integration, manufacturing and costs associated with building next generation multi-gas sensors.

3:00 FEATURED PRESENTATION: Introducing High Accuracy Pressure Sensing into the Consumer Medical Space

Robert Robinson, General Manager, Electronic & Gas Sensing Business, Honeywell

With significant advancement in medical technology, many technological firms are beginning to grasp the opportunity to harness real-time medical monitoring from wearables devices. The progression of technology in the medical grade wearable segment is challenging the age-old perception that high accuracy devices should command high prices. This session will discuss how firms can balance between high accuracy features and cost to help them differentiate in the marketplace

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Tutorials

6:00 Welcome Reception in the Exhibit Hall with Poster Viewing

7:00 End of Day

12月11日(水)

8:00 am Registration and Morning Coffee

全体セッション

8:20 Chairperson's Remarks

Robert Rubino, Senior Director, Research and Development, Integer

8:30 Dexcom's Continuous Glucose Monitoring (CGM) Technology and Its Impact on Diabetes Management, Artificial Pancreas, & Digital Health Systems

Peter Simpson, Vice President of Sensor R&D and Advanced Technology, Dexcom

Recent advances in continuous glucose monitoring (CGM) technology have significantly increased its usability and impact on diabetes management.  CGM's are now widely reimbursed and are rapidly becoming the standard of care for people on intensive insulin therapy.This presentation will provide an overview of Dexcom's CGM sensor technology, its use in digital health and artificial pancreas systems and a preview of our future products.

9:00 Objective Measures for Clinical Assessment and Precise Understanding of Disease Progression

Christopher Hartshorn, PhD, Program Director, Cancer Treatment & Diagnosis, National Institutes of Health; National Cancer Institute

This talk will look at various efforts across the National Institutes of Health attempting to enable more objective measures for out-of-clinic, patient-specific assessment and longitudinal understanding of disease progression in large cohorts.

9:30 Wearable Electrochemical Sensors - Recent Advances

Joseph Wang, Distinguished Professor & Chair, Nanoengineering, University of California, San Diego

This presentation will discuss recent developments in the field of wearable electrochemical sensors integrated directly on the epidermis or within the mouth for various non-invasive biomedical monitoring applications. Particular attention will be given to non-invasive monitoring of metabolites and electrolytes using flexible amperometric and potentiometric sensors, respectively, along with related materials, energy and integration considerations. The preparation and characterization of such wearable electrochemical sensors will be described, along with their current status, future prospects, and challenges. 

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

10:30 Roundtable Discussions

Roundtable discussions are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Each topic is led by a moderator who ensures focused conversation around the key issues of that topic. Attendees choose to join a specific group.

Table 1: Miniaturization for Chemical and Biological Detection

Cory Bernhards, PhD, Research Microbiologist, CBR, Defense Threat Reduction Agency

  • How do you decide what to prioritize?
  • Continuous improvement in sensitivity and specificity

Table 2: Best Practices for AI, IoT, etc

Aminat Adebiyi, PhD, Research Staff Member,Biomedical IoT and Applied Analytics, IBM

  • We hear about what’s worked at conferences, but what about what hasn’t worked?
  • What standards do we like? What don’t we like?

Table 3: The Small Business Innovation Research (SBIR) program and Small Business Technology Transfer (STTR)

Dr. Juan Figueroa, Puerto Rico Science and Technology Trust

  • When was the first time you heard about SBIR/STTR? What are the similarities and differences from what you heard today?
  • Are you aware of any SBIR/STTR award winner? Are you aware of a company with a potential for >$1M equity free and hold on to IP? Why wouldn’t you invest in it/them? Why would you invest in it/them? 
  • Are you afraid the federal government will take the IP? 
  • Are you afraid the grantees (contractors) do not have the experience to move the company forward? 
  • Do you have a horror story about an SBIR/STTR company? A positive story? What went wrong? What went right?
  • What do you want to hear to make you look favorably towards investing in an SBIR/STTR grantee?  

Table 4: Non-Invasive Physiological Monitoring Beyond Activity, PPG, RR and ECG - Adding More Medically Relevant Vital Signs

Ashish V. Pattekar, Principal Scientist, PARC, a Xerox Company

  • What will next generation physiological monitoring sensors and systems look like?
  • What technologies will need to be developed to enable continuous (e.g., wearable) monitoring of additional, medically relevant, vital signs?
  • Can raw data from existing sensors be used to infer other vital parameters using AI / ML approaches?
  • Would there be a net gain from the consumerization of these new sensing modalities (cost versus benefit of resulting follow up / treatment)?
  • What are the risks to the end-user, and can we think of approaches to mitigate them?

Table 5: Considerations for use of Sensor-measured Digital Endpoints during Drug Clinical Development

Mike Benecky, Senior Director, Global Regulatory Affairs in Precision and Digital Medicine, GlaxoSmithKline

  • What further work needs to done to establish an  “off-the-shelf” 510k cleared sensor device as a Digital Clinical Outcome Measure in a Pivotal Drug Study?
  • What added value do digital sensors bring to the drug clinical development process?
  • What are the regulatory challenges during utilization of a novel digital endpoint during a registrational drug clinical trial?
  • What therapeutic areas appear most fertile for use of digital endpoints during drug clinical development

生物学的な脅威への対応

11:25 Chairperson's Remarks

Cory Bernhards, PhD, Research Microbiologist, CBR, Defense Threat Reduction Agency

11:30 The BioACER Sensor: Biological Automated Collector/Detector for Expeditionary Reconnaissance

Cory Bernhards, PhD, Research Microbiologist, CBR, Defense Threat Reduction Agency

We are developing the BioACER sensor, which is a completely novel and fully automated device that conducts remote sample collection (while flying through a plume), preparation, identification, and reporting for biological aerosols within 15 minutes. This unmanned device will allow for low cost, rapid, and accurate identification of biological threats, while eliminating the risk of exposure to operators and allowing for early warning to protect both soldiers and civilian populations.

12:00 pm Nanopore Sequencing for Rapid Identification of Biological Threats in the Field and Biosurveillance

Maria Arevalo, PhD, Research Microbiologist, Defense, Defense Threat Reduction Agency

The warfighter needs quick and relevant information on emerging biological threats that may present themselves in the field. Next-generation sequencing technologies allow for the analyses of whole genomes for unbiased, conclusive identification of pathogens, but can also help to detect and distinguish novel and synthetically modified threats. We are developing rapid sample-to-answer workflows for processing, sequencing, and automated analysis of environmental samples to identify biological threats in the field.

12:30 Sponsored Presentation (Opportunity Available)

1:00 Enjoy Lunch on Your Own

センサーの小型化とポイントオブケア診断

1:55 Chairperson's Remarks

Cory Bernhards, PhD, Research Microbiologist, CBR, Defense Threat Reduction Agency

2:00 Silicon-Based, Miniaturized Sensing Technologies for Real-Time, Multi-Parameter Monitoring

Winny Tan, PhD, Senior Manager, Strategic Alliances, IMEC USA

Continuous analysis of biological and chemical substances offers great promises for applications such as environmental monitoring, diagnostics, precision agriculture, food analysis, and process analytical tools for monitoring pharmaceutical manufacturing processes. However, if we want to realize these promises, we need to drastically decrease the cost, size and power consumption of current solutions - while increasing their performance. Hence the unique value of semiconductor-based technologies and their opportunities for extreme miniaturization and integration of hardware and software algorithms at the sensor node level. This presentation will give an overview of highly compact, yet extremely sensitive sensor and imaging technologies that can be applied for high-throughput, real-time analysis of biological and chemical substances. Detecting heavy metals, pollutants and even bacteria are all part of our roadmap.

2:30 Biosensors for Use in Point-of-Care Applications

Prasad Pamidi, PhD, Director Sensor Development, Instrumentation Lab, Werfen Company

Biosensors applications are rapidly growing in point-of-care testing. The majority of these sensors are used in single use applications and some of them lack operational simplicity or laboratory quality in accuracy and precision. This presentation will focus on addressing common challenges in developing point of care friendly biosensors and recent options to address such gaps in point-of-care testing.

3:00 pm Transforming Health Testing with Saliva

Stan Skafidas, PhD, Chief Technology Officer, MX3 Diagnostics Inc.

Peak physical and mental performance is dependent upon optimal hydration. The development of the MX3 test strip represents the first commercially available saliva-based electrochemical biosensor for hydration testing, measuring salivary osmolarity (SOSM), a sensitive indicator of hydration status. Using the MX3 test strip and MX3 Lab hydration status can be measured directly from the tongue in seconds, providing laboratory- grade, actionable hydration results.

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Tutorials

6:00 End of Day

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新通知サービス
更新履歴
2019/11/19
アジェンダ更新
2019/11/08
スポンサー更新
2019/10/31
スポンサー更新
2019/10/11
スポンサー更新
2019/09/10
スポンサー更新
2019/08/27
アジェンダ・スポンサー更新
2019/07/29
アジェンダ・スポンサー更新







メール配信サービス